what drives us

At Chimerix, we’re committed to driving the development of groundbreaking medicines designed to protect immunocompromised patients from potentially deadly viral infections.

The Need for Antiviral Protection

  • 70K
    Number of hematopoietic cell transplants (HCT) performed each year worldwide1
  • 65%
    Percentage of cytomegalovirus (CMV)-related DNA viral infections that led to hospital readmission after HCT2
  • 0
    Number of approved therapies for the prevention of CMV in HCT recipients3
  • 8-18%
    Percentage of kidney transplant patients who have CMV infection4

development pipeline

Our lead product candidate, brincidofovir, has shown in vitro antiviral activity against all five families of DNA viruses that affect humans, including the herpesviruses and adenoviruses. Brincidofovir has not been associated with kidney or bone marrow toxicity in over 1,000 patients treated to date. Brincidofovir has received Fast Track designation from the FDA for CMV, adenovirus, and smallpox.
Brincidofovir for Adenovirus
Open-label trial designed to evaluate the safety and efficacy of brincidofovir for the treatment of adenovirus infections in pediatric and adult patients.
Brincidofovir for Smallpox
We are working with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure to treat potential smallpox outbreaks in the event of bioterror attacks or accidental release.

disease areas of expertise

Cytomegalovirus (CMV)

Cytomegalovirus (CMV) is a member of the herpesvirus family and remains a significant cause of viral infections in transplant recipients.


Adenovirus, which causes the common cold in people with healthy immune systems, can lead to life-threatening infections in immunocompromised people.


Though smallpox has been officially eradicated, it remains a threat in cases of bio error or as a potential bioterror weapon.